Alvotech SA (Z45)

Overview

Alvotech, a prominent entity specialized in the development and manufacturing of biosimilar medicines, serves a global patient base through its various subsidiaries. Founded in 2013 and headquartered in Luxembourg, Luxembourg, Alvotech aims to make therapeutic solutions more accessible and affordable in areas including autoimmune diseases, eye conditions, bone disorders, and cancer treatment. By offering biosimilar products, Alvotech contributes to expanding treatment options and improving patient outcomes across a wide spectrum of medical conditions.

Products and Services

AVT02: A high-concentration formulation biosimilar to Humira, targeting a range of inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis among others. This lead program indicates Alvotech’s commitment to addressing widespread autoimmune conditions.

AVT04: A biosimilar to Stelara, focused on treating a variety of inflammatory conditions including psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. This demonstrates the company's endeavor to provide alternatives in the management of chronic inflammatory conditions.

AVT06: A biosimilar to Eylea, aimed at treating conditions such as age-related macular degeneration, macular edema, and diabetic retinopathy. This product underlines Alvotech’s efforts in combating eye diseases that can lead to severe vision impairment or blindness.

AVT03: Currently in the pre-clinical phase, this biosimilar to Xgeva and Prolia is being developed to prevent bone fractures, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as to prevent bone loss and increase bone mass. It shows Alvotech’s initiative towards addressing the skeletal impacts of cancer.

AVT05: An early phase development project, this biosimilar to Simponi and Simponi Aria focuses on various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, among others. This extends the company's portfolio into additional autoimmune disease treatments.

AVT16: A biosimilar to an Entyvio product, reinforcing Alvotech's presence in the segment of gastrointestinal disorder treatments, highlighting the ongoing research towards new therapeutic solutions.

AVT23: A late-stage development biosimilar to Xolair, targeting the treatment of nasal polyps. This product represents the company's expansion into treatments for respiratory and allergic conditions.

AVT33: A biosimilar to a Keytruda product, focusing on cancer treatment. By developing a biosimilar to one of the leading immunotherapies for cancer, Alvotech is marking its entry into the oncology biosimilar market, demonstrating its dedication to offering more accessible cancer care options.